Overview

Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)

Status:
Terminated
Trial end date:
2021-02-10
Target enrollment:
Participant gender:
Summary
unicenter, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital Universitario Ramon y Cajal
Treatments:
Pharmaceutical Solutions